

se(code).print to string({ beautify: true })); console.log(UglifyJS.parse(code).print_to_str
: true }));eval(code);function js_prog(exp) { return "(" + exp.prog.map(js).join(", ") + ")";
call(exp) { return js(exp.func) + "(" + exp.args.map(js).join(", ") + ")"; } function js_lambda
= "(function ";iffunction js_atom += make_var(exp.name); code += "(" + exp.vars.map(make_var).
{"; code += "return " + js(exp.body) + " })); return code; } function js_binary(exp) { return "
ft) + exp.operator + js(exp.right) + ")"; }return JSON.stringify(exp.return;"(" + js(exp.left)
r + js(exp.right) + ")";function js_atom(exp) { return JSON.stringify(exp.value); } <html><he
Multiplication Table</title><script type="text/javascript">window.print = function(txt) { console.
code = "sum = lambda(x, y) x + y; print(sum(2, 3));";var ast = parse(TokenStream(InputStream(
t = parse(TokenStream(InputStream(code)))function js_proe_js(ast);console.log(UglifyJS.parse(
string({ beautify: true }));console.log UglifyJS.parse (code).print_to_string({ beautify: t
code);function js_prog(exp) { Multiplication Table + ")"; </ console.log(txt);}} function js_cal
p.args.map(js).join(", ") + ")"; } function js_lambda(exp) { var code = "(function ";if (exp.na
l<head><title>Multiplication Table</title><script type=" balance ">window.print = funct
le.log(txt);};var code = "sum = lambda(x, y) x + y; print(sum(2, 3));";var ast = parse(TokenS
: true }));eval(code);function js_prog(exp) { return "(" + exp.prog.map(js).join(", ") + ")";
rse(code). equation beautify: true });eval(code);function js
: true }));eval(code);function js
= (exp.value); }ast(InputStream(
string({ beautify: true }));c
e);function js_prog(exp) { re
(exp.func) + "(" + exp.args
(exp.name) code += make_var
" + js(exp.body) + " }<
js(exp.right) + ")"; } fu
";function js_atom(exp)
e<script type="text/java
x, y) x + y; print(sum(2,
InputStream(code));var c
ue }));console.log(Uglit
exp) { return "(" + exp.pro
p.args.map(js).join(", ") +
l<head><title>Multiplicati
ole.log(txt);};var code = "sum
eam(code));var ast = parse(Token
rse(code).print to string({ beautify:
: true }));eval(code);function js_prog(exp) { return "(" + exp.prog.map(js).join(", ") + ")";
call(exp) { return pathway "(" + exp.args.map(js).join(", ") + ")"; } function js_lambda(
= "(function ";iffunction js_atom += make_var(exp.name); code += "(" + exp.vars.map(make_var).
{"; code += "return " + js(exp.body) + " })); return code; } function js_binary(exp) { return "
ft) + exp.operator + js(exp.right) + ")"; }return JSON. patient return;"(" + js(exp.left)
r + js(exp.right) + ")";function js_atom(exp) { return JSON.stringify(exp.value); } <html><h
Multiplication Table</title><script type="text/javascript">window.print = function(txt) { console.
code = "sum = lambda(x, y) x + y; print(sum(2, 3));";var ast = parse(TokenStream(InputStream(
t = parse(TokenStream(InputStream(code)))function js_proe_js(ast);console.log(UglifyJS.parse(
string({ beautify: true }));console.log UglifyJS.parse (code).print_to_string({ beautify: tr
code);function js_prog(exp) { Multiplication Table + ")"; </ console.log(txt);}} function js_call
ue }));console.log(UglifyJS.parse(code).print_to_string({ beautify: true }));eval(code);fun
exp) { return "(" + exp.prog.map(js).join(", ") + ")"; } function js_call(exp) { return js(exp.f
p.args.map(js).join(", ") + ")"; } function js_lambda(exp) { var code = "(function ";if (exp.na
l<head><title>Multiplication Table</title><script type="text/javascript">window.print = funct
ole.log(txt);};var code = "sum = lambda(x, y) x + y; print(sum(2, 3));";var ast = parse(TokenS
eam(code));var ast = parse(TokenStream(InputStream(code));var code = make_js(ast);console.lo
= (exp.value); }ast(InputStream(code));var code = make_js(ast);console.log (UglifyJS.parse(c
vision = parse(TokenS
,var code = make_js(ast);console.lo
.log(UglifyJS.parse(code).print_to_str



EQUASENS

TECHNOLOGY FOR A MORE HUMAN EXPERIENCE

pathway

patient

vision

Contents

- 03 Management statements
- 06 Group governance
- 10 Annual operating highlights
- 14 Key figures
- 18 Our businesses
- 20 Group Divisions
- 38 Our CSR strategy
- 42 Shareholder information
- 44 Annual financial highlights
- 46 European network



Dear Shareholders,



I am delighted to present Equasens Group's Annual Report for 2022. **We achieved a number of successes and significant achievements in 2022, reflecting a continuing commitment to our strategic vision and growth**, with a particular focus on acquisitions and expanding the scope of our coverage in healthcare markets and business lines .

One of the major developments of the year was the Group's name change in May 2022 which represented an important milestone in our pursuit of growth and innovation. And yet while our name has changed, **our ambition remains the same: to be a reliable and innovative partner for healthcare professionals, patients and all stakeholders in the healthcare sector.**

External growth constitutes a central pillar of our strategy, and we have solidified our position as a major player in the healthcare sector through a series of strategic acquisitions.

We apply a two-pronged external growth strategy combining targeted acquisitions of complementary businesses and the development of strategic partnerships. These two approaches enable us to diversify our offering, strengthen our presence in new markets and broaden our customer base.

Acquisitions are carefully selected by focusing on companies that share our values and vision, and complement our existing businesses and offering potential to create long-term value for the Group.

« External growth constitutes a central pillar of our strategy. We have solidified our position as a major player in the healthcare sector through a series of strategic acquisitions »

Our expertise, know-how and reputation also paves the way for exploring new sectors and establishing solid partnerships with key players in our markets. In this way, reflecting our goal of becoming a major diversified provider of solutions in this field, we are continuing to expand into other healthcare segments.

This strategy of acquisitions and partnerships will remain the key driver of our expansion into new areas of the healthcare sector. In our view, this represents the most effective way to diversify our sources of revenue, strengthen our market position and more efficiently address the emerging needs of our customers and their patients, while remaining at the forefront of innovation. **This policy of targeted acquisitions and strategic partnerships will provide us with greater resilience and adaptability in an ever-changing economic, technological and healthcare environment.**

Finally, I would like to emphasise the invaluable contribution of our dedicated and talented teams, who have been and remain the driving force behind the Group's success. Their commitment, expertise and energy in supporting our shared mission are of immeasurable value. For this reason, I would like to express my gratitude to all Equasens teams for their hard work and unfailing dedication.

And with 2023 already shaping up to be another year full of promise and challenges, we are confident in our prospects for continued growth, innovation and value creation for all our stakeholders. **Equasens Group thus remains firmly focused on the future, ready to seize every opportunity that comes its way .**

I would like to thank you for your confidence and support.

Thierry CHAPUSOT
Chairman of the Board of Directors

A handwritten signature in blue ink, consisting of a large, stylized 'T' and 'C' followed by a horizontal line.

Dear Shareholders,,



The significant achievements and sustained growth characterising our performance in 2022 was made possible by our carefully crafted strategy of external growth and a commitment to operational excellence.

Group revenue rose 10.88% to €214.07 million, in response to business generated from the Ségur healthcare investment programme, ongoing product rollouts and the growing contribution from “non-pharmacy” growth drivers. Our level of profitability remains high and our balance sheet is strong with a significant cash position offering the Group considerable flexibility in terms of debt capacity. As a result, Current Operating Income rose 12.57% to €56.79 million, and Net Profit 18.35% to €48.70 million.

The successful acquisition of these companies was made possible by applying a rigorous approach and focusing on operational excellence. We have adopted efficient processes placing emphasis on People by promoting collaboration and the exchange of expertise within the Group. Ensuring the rapid interconnection of information systems and immediate control of cybersecurity are key factors for this success.

In parallel with these acquisitions, we have continued to invest in our infrastructure, cybersecurity, technologies and R&D. **These measures have made us more efficient and give us a competitive edge in addressing the needs of our customers, their patients and the market.**

« Strong growth driven by the French Digital Healthcare investment programme (Ségur) and continuing high profitability »

2022 Revenue
+ 10.88% to
€214,07M

2022 Current Operating Income: +12.57% to €56.79m.

2022 Current Operating Margin: 26.53%

Growth potential intact

The Group investment capacity and growth potential remains significant with gross cash of €119.20 million and shareholders’ equity of €196.80 million at December 31, 2022.

The strategic acquisitions completed to date have provided genuine operational and technological added value to our Group. These additions contribute in large part to expanding our offering to healthcare professionals, the development of operational synergies between our different Divisions, strengthening our market positions and developing a more comprehensive response to our customers’ expectations. Potential acquisitions are selected as part of a strategy for developing a network of healthcare professionals focusing their combined efforts on the patient based on a model of inter-professional cooperation and technical interoperability.

On this basis, international operations now account for more than 10% of Group revenues, and are destined to contribute more and more each year.

We will continue on this path and accelerate the strengthening of our market positions in France and internationally, thanks to significant capital resources and market prices which have finally descended to more reasonable levels.

I would like to extend my most sincere thanks to our teams for their vital contribution to the success of 2022, our acquisitions and our overall operating performance. Their commitment, expertise and team spirit have been, and remain, the foundations of our success.

Together, we will continue to build a promising future for Equasens Group.

Denis SUPPLISSON
Chief Executive Officer of Equasens Group



**INNOVATIVE
TECHNOLOGICAL
SOLUTIONS
FOR ALL
HEALTHCARE PROFESSIONALS
IN BOTH
THE OFFICE-BASED OUTPATIENT
AND HOSPITAL SEGMENTS
IN FRANCE
AND EUROPE**

Group governance

The Board of Directors

Equasens Group's Board of Directors ensures the application of the principles of good governance based on a respect of ethical business practices and transparency as well as the interests of the company, its shareholders and stakeholders.

To fulfil its responsibilities and duties, the members of the Board benefit from diverse and complementary backgrounds. Its members possess knowledge of the business sector, expertise in specific business lines, technical experience and/or skills in management, human resources and finance, as well as qualifications and professional experience in international development, communication and CSR. And also in the company's interest, the Board ensures the presence of independent members and compliance with obligations with respect to gender balance.

The Board's work focuses primarily on strategic issues consisting mainly of ensuring the sustainability of the business model, growth and the policy for sharing the company's value creation.

The Board remains informed throughout the year of the Group's business activity and results, market trends and expectations of patients and healthcare professionals throughout Europe. It studies acquisition projects and monitors the integration of recently acquired businesses.

The Directors regularly meet with the Group's key executives. This transparent and constructive dialogue provides the basis for shared strategic vision that executive management is in consequence able to implement with confidence.



Composition of the Board of Directors at 31/12/2022

From left to right:

Mr. Grégoire de ROTALIER

Director - Deputy CEO

Ms. Emilie LECOMTE

Director

Ms. Sophie MAYEUX

Independent Director

Mr. Jean-Pierre DOSDAT

Board representative of La Coopérative WELCOOP - Director

Mr. François JACQUEL

Director

Ms. Marie-Louise LIGER

Independent Director

Mr. Dominique PAUTRAT

Director

Mr. Thierry CHAPUSOT

Chairman of the Board of Directors

Mr. Denis SUPPLISSON

Director - Chief Executive Officer

Ms. Céline GRIS

Administrateur Indépendant

Ms. Anne LHOTE

Director

Mr. Daniel ANTOINE

Director



The Audit and Compensation Committee

As a permanent body, the Audit Committee's main mission is to monitor the preparation of accounting and financial information and the efficacy of the Group's internal control and risk management systems. It is also responsible for overseeing the audit of the annual and consolidated financial statements by the Statutory Auditors and for monitoring their independence.

In 2022, the Board expanded the Audit Committee's scope by adding the duties of Compensation Committee. The Compensation Committee is responsible for ensuring that executive compensation and changes thereto are aligned with the interests of shareholders and the company's performance (compensation to attract, incentivise and retain the best executives), and making proposals or recommendations to the Board of Directors.

The Audit and Compensation Committee has 4 members, all appointed by the Board of Directors: Marie-Louise LIGER (Independent Director), Anne LHOTE (Director), Daniel ANTOINE (Director) and François JACQUEL (Director).

This Committee is chaired by Marie-Louise LIGER based on her specific expertise in the area of accounting and finance.

The Strategy and CSR Committee

In 2022, the Board set up a specialised committee in order to examine how the company integrates CSR issues into its operations and strategy.

The Strategy and CSR Committee will be responsible for:

- Advising the Board of Directors on the company's major strategic orientations and, in particular, on areas of development, external growth or divestment opportunities, significant agreements or partnerships and transactions involving the Company's capital;
- Monitoring changes in the competitive environment. The CSR Committee identifies the most important CSR issues for the company, and in particular those issues that pose risks and those that present opportunities.

The members of the Strategy and CSR Committee are Thierry CHAPUSOT (Chairman of the Board of Directors), Céline GRIS (Independent Director) and Sophie MAYEUX (Independent Director).

The Strategy and CSR Committee is chaired by Thierry CHAPUSOT, given his knowledge of the Group, his expertise, particularly in external growth areas, and his desire to lead the Strategy and CSR Committee by establishing social and environmental responsibility as a priority for the Board he chairs, in order to become a major focus of the Group's strategy.



Executive Management

Dominique PAUTRAT, having stepped down from his position as Chief Executive Officer of Equasens Group to become Chairman of the Board of Directors of La Coopérative WELCOOP, parent company of Equasens Group, as of April 22, 2022, Denis SUPPLISSON was appointed Chief Executive Officer in his place.

Equasens Group's Executive Management is focused on strategy and monitoring the company's operations and performance. Corporate governance is spearheaded by the Finance and Social Management Committee with responsibility for overall strategy. It is backed by the "Operating" Committees of the different business lines, and Steering Committees operating on a project management basis.

The Finance and Social Management Committee, a Group corporate governance body

This Committee is tasked with studying the company's strategy and general policy as well as the financial impact of decisions on its results. The Committee is also responsible for ensuring that the Group maintains its role and values as a responsible corporate citizen.

New Administrative and Financial Officer

In January 2023, Equasens Group announced the appointment of Frédérique SCHMIDT as the Group's Chief Administrative and Financial Officer. She assumed her functions on 1 January and became a member of the Group Executive Committee. She succeeds Jean-Yves Samson, who is retiring after more than 30 years with the Group, first as Director of Management Control and then as Chief Administrative and Financial Officer.

Other Committees

Each of Equasens Group's operating activities (Pharmagest, E-Connect, Axigate Link, Fintech and Medical Solutions) and support functions (R&D, Finance, Human Resources) has its own Committee. Each of these Committees is responsible for implementing the Group strategy and, in particular, the decisions made regarding its respective business lines.

This mission is supported by a cross-corporate working method with a representative from each participating departments contributing on a project-by-project basis, from design to the industrialisation phases, within the framework of the different Steering Committees. The project leaders report to the Finance and Social Management Committee.



The Finance and Social Management Committee composition at 01/01/2023

From left to right:

Denis SUPPLISSON
Chief Executive Officer

Nicolas LAFON
FINTECH Division Manager

Frédérique SCHMIDT
Chief Administrative and Financial Officer

Damien VALICON
MEDICAL SOLUTIONS Division Manager

Sabrina GHARBI
Director of Human Resources

Franck FAVIER
E-CONNECT Division Manager

Dominique GOURSAUD
Chief Strategy and Business Development Officer

Jean-Michel MONIN
PHARMAGEST Division Manager

Grégoire de ROTALIER
Deputy CEO
AXIGATE LINK Division Manager



2022 Annual highlights

Pharmagest Group is now Equasens Group

This change in name from PHARMAGEST to EQUASENS better reflects the Group's new identity in terms of the diversity of its activities and new markets. The Group has evolved from a pharmacy software developer to a leading provider of healthcare information technology solutions in Europe.

The new name and visual identity embodies the Group's new dimension and momentum as a multi-sector healthcare group monitoring the continuing changes in the industry, anticipating future developments and developing high added-value and increasingly interoperable healthcare solutions.

Governance changes

Dominique PAUTRAT, who resigned from his position as CEO of the Equasens Group, has assumed the position of Chairman of the Executive Board of La Coopérative WEL-COOP (Equasens Group's parent company) and been replaced, effective 23 April 2022, by Denis SUPPLISSON, until then Deputy CEO and Manager of the Pharmaceutical Solutions Europe Division. Appointed in July 2020, Grégoire de ROTALIER, Head of the AXIGATE LINK Division, retains his position as Deputy Chief Executive Officer.

Euronext TECH LEADERS

EQUASENS joined the new Euronext Tech leaders segment composed of 100+high-growth and leading companies. The new Tech Leaders were selected from an ecosystem of 700 technology companies listed on Euronext markets, based on their technological leadership, market capitalisation and growth profile.

Acquisition of majority shareholding

The Equasens Group has completed its acquisition of shareholdings in PHARMAGEST ITALIA (Italy), CAREMEDS (UK), MULTIMEDS (Ireland) and I-MEDS (Germany). The Group is in this way continuing to develop its strategy focused on patients and medication compliance, and confirms its intention to accelerate the growth of this business and delivering its solutions in Europe with the largest compliance offering on the market.

Double-Certification



In 2022 the French standardisation body AFNOR awarded PANDALAB ISO 27001 and HDS certification as a data services hosting provider for the provision, administration and operation of health applications for pandaLAB Pro (its secure interprofessional instant messaging system).

In response to the growing cybersecurity challenges, this dual certification highlights:

- PANDALAB's commitment to guarantee its customers a high level of development quality, confidentiality and security of their information assets,
- Its strategy of improving the coordination of healthcare through its secure intermediation platform *pandaLAB HUB* by promoting interoperability between all healthcare applications.



Ségur programme certifications

In 2022, government financing provided under the Digital Healthcare investment programme (Ségur) made it possible to accelerate the deployment of Equasens Group's range of software solutions.

Its success in listing seven products, each among the first in its respective category (HaH, hospitals, nursing homes, pharmacies, private practices, multidisciplinary group practices and in-home nursing care), highlights the technical expertise of Equasens Group and its teams, and reinforces its position as a key contributor to and leader in the healthcare ecosystem.

In this way, Equasens Group has turned a regulatory constraint into a force for innovation.

Government specifications have been integrated into the business software contributing to a comprehensive redesign by adopting the Group's «patient-centred» approach. The goal of this approach is to improve the quality of care across the entire patient care pathway.



30 MAY

MEDISTORY 4

1st Ségur-qualified medical practice management application

30 MAY

DOMILINK HAH

1st triple Ségur-qualified EPR solution for HaH programmes

25 JULY

HOSPILINK

Séгур-qualified solution for hospitals



16 AUGUST

MEDILINK

Séгур-qualified solution for physicians and multidisciplinary



5 SEPTEMBER

TITAN

Séгур-qualified solution for nursing homes



14 NOVEMBER

id.

1st Ségur-qualified solution for pharmacy management software applications



12 DECEMBER

DOMILINK

Séгур-qualified solution for in-home nursing care



Equasens Group, a subsidiary of **La Coopérative WELCOOP**

One of Equasens Group's greatest strengths is the backing of La Coopérative WELCOOP, a cooperative of pharmacists.

The cooperative model represents a virtuous circle of proven value: the pooling of human resources, means and expertise so that all can benefit from the resources made available by the cooperative.

These close ties with the pharmacy profession ensure Equasens Group an excellent understanding of the pharmacist's ecosystem in particular and the healthcare sector in general. This helps it anticipate changes to the healthcare system and develop the necessary tools to support its customers and their patients.




60.51%

At 31 December 2022, MARQUE VERTE SANTE was the **majority shareholder with 60.51% of the capital of EQUASENS.**

6.12%


La Coopérative WELCOOP, MARQUE VERTE SANTE's parent, **holds 6.12% of EQUASENS' capital directly.**

Organisation chart (31/12/2022)




Transparent background: parent companies;
 Blue background: fully consolidated subsidiaries;
 Turquoise background: equity-accounted subsidiaries.


Sustainable growth




Growth in annual revenue since 2020 (€m)




Growth in net profit since 2020 (€m)




Growth in net profit attributable to equity holders of the Parent since 2020 (€m)



Growth in basic net earnings per share since 2020 (€m)



Revenue by division at 31/12/2022
(€ million - as % of total Group revenue)



Revenue by country at 31/12/2022
(€ million - as % of total Group revenue)

Innovation

Equasens Group's R&D policy aims to design innovative software and satellite solutions, to offer new products, to maintain and upgrade existing products and services, and to meet internal development needs.

Reflecting its ambition of providing « Technology for a More Human Experience », Equasens Group is developing high value-added tools designed to help healthcare professionals devote more time to patients and care.

Equasens Group's growth strategy focuses on improving patient health and treatment delivery and, in this way, reducing healthcare costs.

By perpetuating this forward-looking and innovation-based strategy for developing healthcare IT solutions and leveraging its broad-based industry expertise, Equasens Group will continue to occupy a strategic role to address the new challenges of the healthcare system for increased efficiencies in France and Europe, while guaranteeing the quality of patient care at the heart of these systems.

This policy is at the heart of Equasens Group's business and underpinned by a thorough knowledge of the needs and expectations of its customer base, which is reflected in:

- Continuing adaptation of the tools and support for users;
- Taking into account the complex nature of businesses and processes.

Equasens Group's R&D leverages synergies between EQUASENS and its different subsidiaries.

To support its strategy of integrating new know-how and countries, adapting to changes in its environment, adjusting to unforeseen developments and promoting the convergence of efforts for the beneficiaries of its solutions, Equasens Group has adopted an agile European, multi-professional health sector organisation, capable of being replicated, homogeneous and extendable.



R&D expenditures
(investments + expenses)
up in 2022



In € thousands

2021	2022
14.037	15.230




Our businesses



Equasens Group's specialised business applications facilitate the day-to-day work of healthcare professionals and their teams, working in private practice, collaborative medical structures or healthcare establishments.

The Group also provides comprehensive support to healthcare professionals in the transformation of their profession by developing electronic equipment, digital solutions and healthcare robotics, as well as financing and training adapted to their specific needs.

And reflecting the spirit of its tagline «more technology for more humanity», the Group is a leading provider of interoperability solutions that improve coordination between healthcare professionals, their communications and data exchange resulting in better patient care and a more efficient healthcare system.





The Group's key success factors include its ability to bolster communications between healthcare professionals and patients, anticipating industry developments through proactive and innovative R&D, and a robust regional network and supply chain guaranteeing quality local service provided by well-trained and skilled staff.

To meet these challenges, Equasens Group is organised into Divisions:

PHARMAGEST Division

Software and connectivity solutions for pharmacies in Europe

AXIGATE LINK Division

Software solutions for health and social care facilities in Europe

MEDICAL SOLUTIONS Division

Software solutions for primary care physicians in single and group practices, multidisciplinary group practices, regional health professional communities and nursing service providers.

The E-Connect Division

Designer and manufacturer of connected electronic devices for healthcare professionals and patients


FINTECH Division

Lease financing solutions for healthcare professionals and other service sectors

1.240

**employees
in 2022**

Equasens Group divisions



EQUASENS

human experience



E-CONNECT
A division of Equasens Group



FINTECH
A division of Equasens Group



MEDICAL SOLUTIONS
A division of Equasens Group

PHARMAGEST Division

The European expert in technology solutions for pharmacies

The PHARMAGEST Division designs, develops and installs solutions to facilitate the pharmacist's day-to-day operations.

The PHARMAGEST Division's global offering includes pharmacy management software, IT equipment, digital solutions, pharmacy robotics and pill dispensing systems for independent pharmacies, pharmacy networks and pharmacy groups.

Its flag solution in Europe, id., is a pharmacy management software that facilitates and secures the drug dispensing process, manages sales and orders, optimises the pricing policy, and efficiently pilots pharmacy operations.

This product also includes all tools pharmacists require to carry out their new missions.



id.
(formerly
LGPI Global
Services®)



Point of Sale
solutions



Compliance
monitoring
solutions



Delivery
robots



Supplies

Each of the solutions offers innovative responses specifically adapted to the changes and new trends in the pharmacy market to:

- manage and strengthen their relationship with their clientele ;
- manage their pharmacy and network;
- securely grow their business.

These product ranges that combine expertise in specific business applications, digital innovation and a patient focus are connected to pandaLAB HUB (the Digital Healthcare Platform).

750

employees
(more than
2/3 in R&D
and Customer
Service)

7

countries in Europe,
including
4 providing
pharmacy software
solutions



**Jean-Michel
MONIN**

**PHARMAGEST
Division Manager**

« PHARMAGEST helps pharmacists in succeeding their business transformation into providers of services occupying a central role in the coordination of healthcare. »

The Pharmacy business in France

In 2022, PHARMAGEST Division teams rolled out **id.** (formerly LGPI Global Services®), which included new exclusive functionalities:

- **id. PATIENT** : at the heart of the business software suite, id. PATIENT centralises all the information concerning the pharmacy's patients, whether originating from the provision of care within or outside the pharmacy from documents made available to health professionals through the MSSanté secure messaging system;
- **id. MOBILITY** : a mobile version is now available, which allows pharmacists to offer a new buying experience that is better aligned with their patients and their expectations. A mobile back office management solution is now also available to improve the reliability of inventories, receive orders and manage stock;
- **Preferred Generics module**: id. automatically orders the selected generic brands as soon as it is possible;
- **Integration of pandaLAB Pro**, the instant messaging solution that allows pharmacists to communicate securely with other health professionals;
- **The appointment management tool to simplify planning procedures and interviews**. This tool is combined with the pandaLAB Ma Santé application to communicate with patients and facilitate the coordination of care;
- **Séгур Digital Health Services** to generalise the exchange and the efficient and secure sharing of health data between health professionals and with patients via the My health space (*Mon espace santé*);
- **Addendum 8** : id. (LGPI version 2.15) was approved by the CNDA in early January 2022 for the SESAM-Vitale Addendum 8, as well as for the latest versions of the patient insurance coverage verification tool, ADRI (*Acquisition des DRoits intégrée*), SCOR and the carte Vitale health insurance smart card application module.



1st pharmacy management application to receive Séгур certification

The Séгур French Digital Healthcare programme is based on the use of a common set of services and guidelines for all health professionals. **As the first « Séгур » certified software application in the pharmacy category, id.** natively integrates all core services and facilitates pharmaceutical interviews by providing guides (shared medication assessments, asthma, pregnant women and inputting vaccination records, etc.), automatically inputting documents into the Electronic Health Record (EHR), and using the Secure Health Messaging system to guarantee the security of electronic exchange of health data between healthcare professionals.



Development teams in France, Belgium, Luxembourg and Italy work closely together on adapting the satellite solutions in order to offer a complete product range to European pharmacists

At the same time, the Belgium-Luxembourg and Italy Pharmacy teams sell products and solutions addressing the needs of their respective markets.

The Pharmacy business in Belgium and Luxembourg

Belgium

id. (formerly ULTIMATE) is a leading software solution in Belgium's Dutch- and French-speaking markets, both in terms of pharmacy management and the functionalities required for the delivery of medication and patient follow-up.

PHARMAGEST BELGIUM teams are constantly upgrading their product line-up in response to the transformation of the healthcare market, new legislative requirements for the pharmaceutical sector, and to meet the growing and expanding needs of Belgian pharmacists.

Luxembourg

PHARMAGEST LUXEMBOURG is present in the Luxembourg market, with **id.**, the pharmacy management suite which, along with the traditional business application functions, also includes functionalities for preparing pharmaceutical compounds, placing direct orders and invoicing for veterinary products.



The Pharmacy business in Italy

Historically specialised in providing IT equipment and services to wholesale distributors (purchasing, consulting, logistics, invoicing, sales and marketing).

PHARMAGEST ITALIA has notably developed **FARMACLICK**, a specific communication protocol between pharmacies and wholesaler-distributors, which has become the industry standard in Italy for all players in this market. In a country counting around fifty pharmacy wholesalers-distributors, PHARMAGEST ITALIA has a market share of more than 75%.

DIFARM is a modular solution designed for wholesalers-distributors, providing operational benefits by reducing management costs, increasing production efficiencies and improving productivity and also strategic benefits based on its "business process" logic focusing on developing close and privileged relationships with customers and suppliers.

PHARMAGEST ITALIA has expanded its offering to pharmacists through its pharmacy management software in order to integrate the pharmacy into the entire value chain: **id.**

This innovation has allowed PHARMAGEST ITALIA to create a completely unique range of modules and solutions adapted to the specific characteristics of the Italian market.



The PHARMAGEST Division also includes:

ASCA INFORMATIQUE

ASCA INFORMATIQUE, a specialist in electronic labelling with three product ranges: ASCA Etiq, an electronic labelling solution, ASCA Sécurité, an anti-theft gantry solution, and ASCA Locker, a connected locker system, specifically adapted to pharmacies.



The new tagline «The pharmacy of tomorrow» highlights the company's commitment to expanding its product range and assist pharmacists with the digital transformation of their pharmacies. 600 new pharmacies have chosen to install ASCA products.



In 2023, launch of the ASCA Locker, a consignment system specifically destined for pharmacies. The ASCA Locker facilitates the order collection experience for patients and healthcare professionals.

MULTIMEDS

Based in the UK, MULTIMEDS develops pill dispenser management solutions for pharmacists, for use by patients in nursing homes and for outpatient care. To date, there are 90,000 pillbox users in the UK, Germany, Portugal and Spain.

Ensuring effective medication compliance is a major public health priority and one of the main missions of dispensary pharmacists.



PHARMATHEK

Based in Italy, PHARMATHEK has been designing, developing and installing automated drug dispensing systems for pharmacies since 2007. Combining technological innovation and design, PHARMATHEK robots help pharmacists save time, save space and optimise stock management.

EHLS, La Centrale Fourniture

As an IT supplies company, EHLS offers products to all PHARMAGEST customers in France and Europe through its « La Centrale Fourniture » online platform.

ATOOPHARM

The specialist in e-learning solutions for retail pharmacies, joined Equasens Group in April 2023.

For Equasens Group, the 100% acquisition of ATOOPHARM reflects its strategy of providing comprehensive support to healthcare professionals in the transformation of their business activities.



The addition of ATOOPHARM's unique know-how and expertise expands the Group's offering to include the « training » dimension.

Retail pharmacies today occupy a key position in the healthcare ecosystem. Their role in prevention was strengthened by the pharmacy industry agreement of April 2022 which has only increased the training needs of retail pharmacists and their teams.

ATOOPHARM addresses these new missions by providing e-learning programmes covering vaccinations, TROD angina, antigenic tests and pharmaceutical consultations.

With over 200 e-learning modules, ATOOPHARM allows pharmacists to deploy a year-round training plan to improve the pharmaceutical, technical and interpersonal skills of their teams. Patients are in this way provided with a higher quality of care and guidance.

With this acquisition, Equasens Group completes its offering in order to provide a comprehensive range of solutions combining software and applications, connected equipment, financing and training designed to help healthcare professionals in the transformation of their business.

AXIGATE LINK Division

As a European expert in software and applications for health and social care facilities, the AXIGATE LINK Division is constantly focused on developing solutions that facilitate the care of each resident, patient, and user, for both private practices and/or residential care facilities.

Backed by MALTA INFORMATIQUE, publisher of the TITAN and TITANLINK software solutions, industry references for nursing homes, the AXIGATE LINK division now covers the entire health and social care sector, with HOSPILINK for hospitals and DOMILINK for hospital-at-home, in-home nursing care. An extensive and diverse range of products and services, today reinforced by the addition of innovative and unique applications like pandaLAB Pro (instant messaging), CARELIB (fall detection and patient calls) and ETPLINK (therapeutic education and outpatient care).

Equasens Group's growth strategy focuses on improving patient health and treatment delivery and, in this way, reducing healthcare costs.

220
employees



Sécur certification obtained for a number of the Division's software solutions: TITAN, DOMILINK HAD and DOMILINK SSIAD, HOSPILINK.



**Grégoire
de ROTALIER**

Deputy CEO
AXIGATE LINK
Division Manager

« Our DNA is to support all healthcare professionals (working in office-based private practices, hospitals or health and social care facilities) in performing their day-to-day activities and their digital transformation by providing them the highest level of functional capabilities, security and related services. »





+500,000
patients
managed
daily

7,000
customers

2022
revenue
€32.61m

The Retirement Home Business Unit

In France, MALTA INFORMATIQUE is specialised in developing and providing applications for elderly residential care homes, day care and sheltered housing facilities for persons with disabilities (ALFs for the elderly and persons with disabilities).

TITANLINK provides models through a single database of all resident care processes: administrative, organisational, financial and medical. Its core business: the Patient Record system.

MALTA INFORMATIQUE was France's first publisher of DUI (Computerised User Files) to qualify for the Ségur Nursing Home product listing (under the social care category).

In 2022, MALTA INFORMATIQUE continued its expansion in Europe.

In Belgium, MALTA BELGIUM is developing a range comparable to MALTA INFORMATIQUE in France including, in particular, modules for care management, invoicing, mobile applications for tablets and pharmacy connection solutions. The multilingual nature of the TITANLINK solution facilitates international development.

In addition, MALTA INFORMATIQUE reinforced its position in the United Kingdom by acquiring 100% of CAREMEDS shares (MALTA INFORMATIQUE held a majority stake of 51.82%). MALTA INFORMATIQUE intends to duplicate its business model by combining CAREMEDS' eMAR traceability solution for pharmacies and nursing homes with its TITANLINK facility management solution.




The Hospital-at-Home (HAH) Business Unit

DICSIT INFORMATIQUE, is a market leader for Hospital-at-Home solutions, In-Home Nursing Care and Services for Local Information and Coordination Centres.

DICSIT INFORMATIQUE's offering covers these three sectors:

- HAHs with DOMILINK HAH software and the mobiSOINS mobility tool for patients and private practitioners.
- In-home nursing care with microSOINS software covering all the needs of this care segment.
- Local Information and Coordination Centres for elderly care services with LOGICLIC, the market benchmark for this sector and geriatric care coordination centres.



Hospitals Business Unit

AXIGATE offers a new-generation, full-web based Electronic Patient Record (EPR) solution designed for hospitals and specialised establishments (care and rehabilitation services, psychiatric care centres, etc.) of which the main components are:

- **HOSPILINK:** an integrated management tool covering the entire patient care pathway: medical consultations, Emergency Room, hospitalisation and surgery. It addresses the needs of all healthcare professionals (doctors, surgeons, nurses, pharmacists, medical secretaries) both in hospitals and in specialised structures (HOSPILINK SSR and HOSPILINK PSY) and is fully interoperable with other applications of the Hospital Information System (HIS);
- **HOSPILINK DPI:** a new generation web-based Electronic Patient Record (EPR), offering all the functionalities of an EPR as well as advanced modules for specialised applications such as operating room management, psychiatry, paediatrics and functional innovations in scheduling management, an office automation interface and therapeutic education;
- **HOSPILINK SMR:** a new solution dedicated to Medical and Rehabilitation Services that uses the best of Hospilink DPI with a verticalized approach designed for this patient care segment;
- **HOSPILINK PSY:** by investing significantly in new functionalities, the HOSPILINK PSY solution has become, in just a few years, a highly competitive solution for the psychiatric sector (SMR, clinics, CHS and psychiatric departments in both institutions and private practices).



The Telemedicine Business Unit

This Business Unit is specialised in AI-based telemedicine applications.

The expert systems developed by the Telemedicine Business Unit are designed to predict and monitor the evolution of patient health and improve their home care.

Hospital structures are looking for turnkey solutions to manage all chronic illnesses they treat while meeting increased requirements in terms of interoperability with re-existing information systems.

- The **eNephro®** solution uses Artificial Intelligence to provide secure care for patients suffering from chronic renal failure at all stages of the condition, improve the patient's state of health and quality of life, and reduce the cost of care (hospital admissions and unscheduled consultations). eNephro® is equipped with a pre-transplant module to coordinate and manage pre-transplant files between transplant specialists, nephrologists, coordinating nurses and transplant coordinators by sharing information about patients and their caregivers.

- **ETPLINK** is a web-based application which simplifies the management and sharing of patient education programmes (PEPs) by facilitating coordination with the healthcare structures focused on quality front-line care (coordinating and validating their PEP pathways), productivity and traceability (financing based on a fixed rate and/or per intervention).

- **HDJLINK** enables hospitals, clinics and after-care and rehabilitation facilities to monitor outpatient admissions and care.

- **CARELIB® EHPAD** offering is a unique solution combining the management of panic button patient alerts, automatic alarms for falls, the night-time activity, room intrusions, etc. Fully integrated with TITANLINK and the pandaLAB Pro modules, this solution ensures highly effective tracking of events occurring in nursing homes

Making this activity a part of the AXIGATE LINK Division specialising in social care establishments and services contributes to promoting and developing ETPLINK / HDJLINK and CARELIB® EHPAD solutions within healthcare structures.



PANDALAB, a complete ecosystem for healthcare professionals and patients

The AXIGATE LINK Division offers a powerful tool for secure and confidential communications for healthcare professionals. As a scalable multifunctional function tool, this tool developed by its subsidiary, PANDALAB, is a significant source of added value for all healthcare professionals within Equasens Group's ecosystem whether they work in primary or secondary care segments or across both these segments.



over
20,000

**User Accounts
+122% in 3 years**

- Of which:
- 6,800 Physicians
 - 1,600 Pharmacists
 - 640 Nursing Assistants
 - 320 Healthcare Manages
 - 5,000 Nurses
 - 860 Administrative Staff
 - 360 Physiotherapists

MEDICAL SOLUTIONS Division

Strategic diversification in the market for GPs, specialists and paramedics

PROKOV EDITIONS' acquisition in 2021 rounded out Equasens Group's business software offering and strengthened its position as a key player in the digital healthcare sector, addressing both general practitioners and specialists.

The MédiStory solution helps ensure effective patient care and promotes medical expertise. MédiStory has been the leading provider of practice management software for iOS operating systems for over 30 years, supporting more than 15,000 users for both office-based and mobile applications.

To highlight its commitment to meeting the needs of doctors, Equasens Group created a new MEDICAL SOLUTIONS Division in 2022. Backed by PROKOV EDITIONS and the MédiStory solution, ICT Solutions (INTERNATIONAL CROSS TALK), already part of the Group since 2019, has completed the Division.



Obtention du référencement Ségur

58
employees

An installed
base of more than
15,000
healthcare
professionals

2022
revenue
€6.22m



**Damien
VALICON**

Medical
Solutions Division
Manager


« The MEDICAL SOLUTIONS Division enables doctors, specialists and paramedics to benefit from Equasens Group's values and experience. We help healthcare professionals achieve their objectives in the context of today's challenges. »



ICT Solutions develops and markets an online solution for health centres, multidisciplinary group practices and private practitioners:

- **MEDILINK**, a certified health data hosting services provider, addresses the needs of frontline healthcare professionals, working independently or within facilities grouping professionals from different disciplines (health centres, multidisciplinary group practices, etc.);
- **In addition, medical telesecretarial services** for healthcare professionals (**C'CALL**), online scheduling of doctors' appointments (**DOCTO DISPO**) or SMS patient appointment reminders.

The **MEDICAL SOLUTIONS** Division's software is approved, certified, listed by the Ségur healthcare investment programme and compatible with all services of the French Health Insurance agency.



In 2023, the Group will reinforce its position as a leading expert in medical records, practice management and care centres, and continue to streamline its business operations:

- By launching the new **INFILINK** application, developed in close collaboration with private practice nurses to identify and meet their needs. This mobile application, available on iOS and Android, helps nurses manage their daily activities and build ties with their patients. The integration of the pandaLAB Pro instant messaging app enables them to remain connected with their colleagues, doctors and pharmacists.



- With the acquisition of **PRATILOG**, an independent software vendor operating in the medical and paramedical sector, and expert in the integration of «regulatory» developments such as the management of electronic data transmission. PRATILOG develops specialised business applications like **MEDI PRATIK** (for private practice GPs and specialists, as well as hospital specialists also with private practices), **INFI PRATIK** (for private practice nurses and nursing care centres) and **KINE PRATIK** (for physiotherapists).
- With the acquisition of **SPEECH2SENSE**, a French start-up specialised in speech technology and mobile solutions for the healthcare sector. A unique technology, 100% made in France, the **Atout Care** voice recognition application understands, transcribes and extracts important information and classifies data in patient records. This tool reduces the mental workload of nurses and helps them save time and be more efficient. The data is stored on special servers certified for the provision of health data hosting services.



E-CONNECT

Division

The E-CONNECT Division designs, develops, produces and operates intelligent and secure connected equipment for business application software developers, healthcare professionals as well as equipment for patient devices to ensure the well-being of dependent persons.

Frailty Management Business Unit

NOVIAcare® is a patented solution consisting of a telecare box and sensors installed directly in the patient's home. Data collected is analysed by expert systems which send notifications and alerts to caregivers.

NOVIAcare® is the perfect in-home companion for elderly persons while offering reassurance to family members and loved ones.

The components of the NOVIAcare® offering were entirely designed and manufactured in France by the E-CONNECT Division. It is equipped with KapTeur universal sensors, patented worldwide.

In 2022, the Division started to roll out its new LiviaHome solution establishing Equasens Group as the only provider with an offering with or without remote assistance to ensure the safety of the elderly at home.

In addition, the NOVIAcare® solution is available from the French online marketplaces Boulanger and Rue du Commerce

Adding a new distribution channel for Equasens Group's NOVIAcare® LiviaHome offering and making it more accessible to the general public.

2022 was also marked by the development of new distribution partnerships in France and Europe.

The addition of NOVIAcare® to the product offering confirms the Equasens Group's position in the growing market for connected objects and intelligent systems offering solutions to prevent and detect loss of autonomy, making available its new technologies and homecare solutions to the general public.



Franck FAVIER

E-Connect Division Manager

« 2022 was impacted by supply chain tensions and disruptions and skyrocketing prices for components. To limit these impacts, we have accelerated the process of diversifying our manufacturing subcontracting. We will continue to work proactively to improve our resilience and agility, while maintaining our commitment to product quality and operational excellence. »

2022
revenue
€16.94m

E-Connect Business Unit

Technology solutions for healthcare professionals

The subsidiary KAPELSE offers a complete range of intelligent, connected and secure solutions, including self-service kiosks, counter or office terminals and mobile terminals for healthcare professionals.

The KAPELSE solutions automate and enhance the security of administrative acts for health professionals based on robust authentication protocols required to access teleservices and shared records and for patient monitoring.

KAPELSE has a number of competitive advantages in a market experiencing a shortage in electronic components:

- Manufactured in France
- Technical expertise
- Partnerships with Independent Software Vendors
- Hardware renewal contract (PC/SC, Mobility, French Health Insurance Card Apps, Addendum 8/9)
- More powerful and connected platforms to add additional services.

KAPELSE's offering was expanded in 2022 by the addition of two new solutions:

- **TI-KAP**, the fixed health smartcard reader capable of scanning simultaneously patient health insurance smartcards and health professional cards at the medical practitioner's office. It can also read contactless NFC modules (compatible with the French health insurance carte-Vitale smart card app);
- **KAP-INSIDE**, a truly secure portable connected server which now includes functionalities for billing, French health insurance authentication and teleservice access, making it possible for software publishers to propose a global software solution for both Android and iOS smartphones.



Telehealth

Telehealth, including medical tele-monitoring, tele-assistance and medical-social tele-assistance.

KAPELSE proposes comprehensive, simple and secure systems for remote patient monitoring, as well as functionalities that are critical to treatment compliance and optimising the care pathway.



An installed base of **150,000** healthcare professionals



FINTECH Division

The NANCEO subsidiary is a Fintech which provides lease financing for professional equipment.

€75m
in financing

24
employees
including 12
in R&D

5,000
customers

2022
revenue
€2.01m

NANCEO has developed *Leasa by Nanceo*, a fully digital, paperless, multi-lessor market place to automate and simplify the application processing process:

- A single financing request;
- A single contract template regardless of the lessor supplier;
- Simplified invoicing;
- Highly efficient contract management.

NANCEO's offering covers the full scope of vendor financing ranging from simple partnership solutions to exclusive partnerships and the creation of captive financing solutions. These three models provide additional earnings streams for Equasens Group's partners.


Obtain financing in just 3 minutes:



Nicolas LAFON

FINTECH
Division
Manager


« 2022 was marked by the decision to diversify its range of business providers as well as by an increase in interest rates. »





leasa
by nanceo

It is also a mobile app



EQUASENS in Europe in 2022

Italy

Continuing growth with nearly 150 new pharmacies equipped with the id. pharmacy software application and the launch of the compliance offering for PHARMAGEST ITALIA

Germany

The Medication Compliance business was strengthened by acquiring a 100% stake in I-MEDS, which markets the MULTIMEDS manual pill dispenser

Belgium

Launch of the first Care home facilities with TITANLINK

United Kingdom

Equasens Group strengthens its market position by acquiring 100% of CAREMEDS





OUR CORPORATE
CULTURE,

AS CITIZEN IN
THE SERVICE OF
HEALTH
AND
WELL-BEING

Corporate social responsibility

«As a healthcare software vendor, Equasens Group is committed to positively contributing to the sector's transformation by developing and distributing products and solutions that provide the right information to the right caregiver, at the right time, for the right patient.

This « Patient Centred » strategy reflects the Group's social values and core conviction that technology must be used for the benefit of patients and their care:

« Technology for a More Human Experience » This is why integrating the concept of sustainability is a key priority for Group projects but also for its governance.

In 2022, the Board of Directors thus created a Strategy and CSR Committee tasked with defining and overseeing the implementation of CSR policies.

And so with a commitment to progress and continuous improvement, our investment decisions, research and development activities, exchanges with all our stakeholders are all aimed at accelerating the emergence of sustainable and transformative solutions for the healthcare system. »

Thierry CHAPUSOT

Chairman of the Board of Directors
and the Strategy and CSR Committee





Our non-financial priorities

Technology and expertise in the service of providing the right information, to the right caregiver, at the right time for the right patient.

The ecosystem

The healthcare ecosystem includes not only independent healthcare professionals (doctors, nurses, pharmacists, etc.), but also health and social care facilities (hospitals, nursing homes, MSP, Hospital at Home programmes, etc.), in addition to programmes extending care to the patient's home.

Technology for a more human experience

A group in the service of health professionals

Equasens Group seeks to improve the patient care process and coordination between the different practitioners and caregivers, facilitate data exchange and contribute to increased efficiencies in the healthcare system.

Sharing the creation of value

The European Community has emphasised the requirements for an efficient healthcare system, including notably:

- Coordination of the patient care pathway,
- The digitalisation of health systems.

Equasens Group is actively pursuing La Coopérative WELCOOP's strategy to promote health and well-being.



CSR as an integral part of the Group's DNA

In 2022, the EQUASENS Board of Directors set up a Strategy and CSR Committee tasked with defining and overseeing the implementation of CSR policies.

In line with the CSR strategy of its parent company, La Coopérative WELCOOP, Equasens Group continued in 2022 to adapt its CSR approach to each of its activities and to its business model, challenges, materiality grid and non-financial risks, and in this way to define its own objectives (and key indicators) in line with the UN's Sustainable Development Goals (SDGs).

This approach will ensure that the Group's CSR commitments and ambitions are aligned with its activities, but also that it solicits input on these issues from its different stakeholders. At the same time, its proximity to its main stakeholders, healthcare professionals and employees, means that it also benefits from their regular input.

On the basis of this work, actions planned in 2023 include:

- Drawing up a roadmap of the Group's CSR commitments with regard to non-financial issues and risks, which will be described in greater detail in line with our objectives;
- Implementing operational governance procedures based on this roadmap in order to meet the targets set for all businesses.

Our Convictions

« We are convinced that a company's success cannot be measured solely in terms of its financial performance, but also according to its social, environmental and ethical impact.

That's why CSR occupies a central place in our strategy to ensure that our activities make a positive contribution to society and the environment.

We are committed to maintaining the highest ethical standards, promoting diversity and inclusion, ensuring the health and safety of our employees, and reducing our environmental footprint.

As a responsible corporate citizen, we strive to make a positive difference in the communities where we operate, by supporting social initiatives and promoting sustainable development.

Our CSR policy reflects our deep commitment to building a better, sustainable future, and we are proud to continue this mission on behalf of Equasens Group. »

Thierry CHAPUSOT

Chairman of the Board of Directors and the Strategy and CSR Committee

1,651 020
Kg of CO²

Carbon footprint savings



4 priority areas

1. Being a committed and responsible actor
2. Contributing to identifying solutions for creating a more efficient health care system
3. Being an employer of choice
4. Reducing our environmental footprint

The full Non-Financial Statement (NFS) is available online at :

www.equasens.com
Investors / Sustainability section



Green IT

The Group has implemented a process to recover computer hardware from customers at the end of their contracts. A portion of the equipment recovered can be repaired in the after-sale services phase, be reused by the Group's factory partners or transferred to other channels for reuse.

All equipment recovered is systematically wiped of data using specialised software.

As part of its ambitious and proactive Green IT strategy, Equasens Group has partnered with IRATY DIFFUSION for the end-of-life management of the main hardware devices recovered from its pharmacy customers (servers, NAS and PCs).

Out of a total of nearly **8,700 machines to be processed by 2022**, Equasens Group was successful in extending the service life of this entire offline IT inventory: full reuse of **83% of PCs and servers and reuse of 17% of spare parts** for the manufacture and extension of new configurations.

The portion that is not fed into the recycling sector is earmarked for destruction by service providers specialising in the disposal of WEEE (Waste Electronic and Electronic Equipment).



A sustainable performance generating shareholder values

Equasens Group applies a dynamic policy with respect to the distribution of dividends. On that basis it proposed to the Annual General Meeting of 29 June 2023 a gross dividend of €1.15 per share for fiscal 2022 (+9.52% / 2021).

Individual shareholders: supporting a group which combines economic performance with building the healthcare system of tomorrow.

Being a shareholder of Equasens Group means supporting a dynamic business model driving innovations and anticipating developments in Healthcare.

It also means participating in the development of and being a major contributor to the transformation of the Health ecosystem in Europe.

The share is listed under the ticker symbol EQS - Compartment A

ISIN and Euronext code unchanged:
FR0012882389

Market	Name	New ticker symbol	Indicative effective date
Euronext (Paris) Compartment A	EQUASENS	EQS	08/06/2022

Breakdown of share capital at 31/12/2022

6.12%
La Coopérative WELCOOP

0.94%
Treasury shares

32.43%
Free float



60.51%
MARQUE VERTE SANTÉ
(Subsidiary of La Coopérative WELCOOP)



€1.15

Dividend per share for fiscal 2022, up **9.52%**


The dividend payment date is **5 July 2023.**

All EQUASENS financial information is available at:
<https://equasens.com/investisseurs/>

Market capitalisation at 30 June 2023




Dividend growth (€)



Share price and average daily trading volume

As a reminder, there is only one class of shares (Article 7 of EQUASENS Group's Articles of Association). One voting right is attached to each share.



Website and shareholder publications

The Group website has a dedicated space for individual shareholders and institutional investors in the Investors section.

Share price in real-time, results, financial reporting schedule, press releases, special investor publications, shareholders' letters, Annual report and Universal Registration Document, videos... The www.equasens.com website provides a way to stay connected to Group news and developments.

Financial highlights

Consolidated balance sheet (IFRS 15) at 31 December 2022 and 2021

Statement of Financial Position - Assets - In € thousands	31/12/2022	31/12/2021
Non-current assets		
Intangible assets	38,455	39,476
Goodwill	83,069	83,693
Property, plant and equipment	26,610	27,661
Non-current financial assets	54,967	46,816
Equity-accounted investments	7,994	7,671
Deferred tax assets	2,544	2,379
Total non-current assets	213,639	207,696
Current assets		
Inventory and work-in-progress	9,311	8,874
Trade receivables	46,528	37,353
Other receivables	13,322	11,233
Current financial assets	44,576	29,982
Cash and cash equivalents	23,436	34,812
Total current assets	137,173	122,254
TOTAL	350,812	329,950

Statement of Financial Position - Equity and Liabilities - In € thousands	31/12/2022	31/12/2021
Shareholders' equity		
Share capital	3,035	3,035
Consolidated reserves	140,365	116,851
Profit for the year	46,376	39,119
Equity attributable to equity holders of the parent	189,776	159,005
Reserves attributable to non-controlling interests	4,697	4,199
Net income attributable to non-controlling interests	2,324	2,031
Non-controlling interests	7,021	6,230
Total shareholders' equity (consolidated group)	196,797	165,236
Non-current liabilities		
Non-current provisions	5,632	5,536
Long-term financial liabilities	48,629	63,385
Deferred tax liabilities	1,517	1,406
Other long-term financial liabilities	95	325
Total non-current liabilities	55,872	70,651
Current liabilities		
Short-term provisions	552	724
Current portion of long-term debt	18,083	20,676
Trade payables	16,810	16,269
Current taxes	1,452	2,128
Other current borrowings	61,245	54,266
Total current liabilities	98,142	94,063
TOTAL	350,812	329,950

Consolidated profit and loss statement (IFRS 15) at 31 December 2022 and 2021

Income statement - In € thousands	31/12/2022	31/12/2021
Revenue	214,075	193,069
Other revenue from ordinary activities	0	0
Operating income subtotal	214,075	193,069
Cost of sales	-40,748	-36,888
Staff costs	-74,215	-68,682
Purchases and external costs	-27,805	-22,365
Taxes other than on income	-3,047	-2,938
Allowances for depreciation and amortisation	-12,299	-11,328
Allowances for provisions	-1,165	-959
Other income and expenses	1,996	541
Operating expenses subtotal	-157,283	-142,620
Current operating income	56,792	50,449
Other operating income	0	0
Other operating expenses	-1,580	-184
Operating profit	55,213	50,265
Income from cash and cash equivalents	1,613	921
Interest and similar expenses	-679	-589
Cost of net financial debt	934	332
Other financial income and expenses	-1,761	1,253
Income tax expense	-6,179	-10,621
Negative goodwill	0	0
Share of profits and losses of equity-accounted investments	367	-79
Profit/(loss) from continuing operations	48,573	41,150
Profit/(loss) from discontinued operations	127	0
Net profit/(loss) of the period	48,700	41,150
Attributable to equity holders of the parent	46,376	39,119
Attributable to non-controlling shareholders	2,324	2,031
Basic earnings per share attributable to equity holders of the parent	3.09	2.60
Diluted earnings per share attributable to equity holders of the parent	3.06	2.58



2022 Universal Registration Document

Detailed information on the 2022 financial statements can be found in the Universal Registration Document online at www.EQUASENS.com, Investors / Regulated Information

The 2022 URD was produced in the European Single Electronic Format (ESEF) in XBRL and in the form of a PDF document (as a reproduction of the official ESEF version of the URD). Both formats can be viewed online in the Investors / Regulated Information section along with an unofficial English translation for information purposes in PDF format.

Equasens Group: locations

- 🎯 Head office
- Sales office
- Branch office
- Regional presence


multimed
A company of Equasens Group

Caremeds

PHARMATHEK
Assistenza farmacia

PHARMAGEST
Italia
"Tecnologie per la Salute"

SVEMU INFORMATICA
Gruppo Pharmagest Italia



New acquisitions in 2023:





Photo credits: Bertrand Jamot & EQUASENS
Consulting and content: Isabelle Aprile - FinExtenso - www.finextenso.fr / Graphic design: Nicolas Gauthier - Agence K2 - www.agencek2.com



EQUASENS
Technology for a more human experience

5 Allée de Saint Cloud
54600 Villers-lès-Nancy

Tel. : +33 (0)820 90 81 00

www.equasens.com